FDA Approves Hikma’s Generic GLP-1 Agonist for Type 2 Diabetes Posted on December 24, 2024 by admin Approval marks the first generic version of liraglutide injection, referencing Victoza, for improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, alongside diet and exercise.